Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation.
Nikolaos D KarakousisLampros ChrysavgisAlkistis PapatheodoridiAigli-Ioanna LegakiPanagiotis LembessisEvangelos CholongitasAntonios ChatzigeorgiouGeorgios PapatheodoridisPublished in: Pathogens (Basel, Switzerland) (2023)
Both circulating levels of cf-DNA and 5-methyl-2'-deoxycytidine might be useful biomarkers in order to monitor liver disease activity and response to antiviral treatment in HBeAg-negative chronic HBV patients, but further studies are essential in order to validate these intriguing findings.
Keyphrases
- hepatitis b virus
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- ankylosing spondylitis
- ejection fraction
- rheumatoid arthritis patients
- chronic kidney disease
- newly diagnosed
- cystic fibrosis
- prognostic factors
- juvenile idiopathic arthritis
- liver failure
- patient reported outcomes
- cell free
- drug induced